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Summary
 
The plasminogen/plasmin system has the potential to affect the outcome of inflammatory dis-
eases by regulating accumulation of fibrin and other matrix proteins. In human and experimen-
tal crescentic glomerulonephritis (GN), fibrin is an important mediator of glomerular injury
and renal impairment. Glomerular deposition of matrix proteins is a feature of progressive dis-
ease. To study the role of plasminogen and plasminogen activators in the development of in-
flammatory glomerular injury, GN was induced in mice in which the genes for these proteins
had been disrupted by homologous recombination. Deficiency of plasminogen or combined
deficiency of tissue type plasminogen activator (tPA) and urokinase type plasminogen activator
(uPA) was associated with severe functional and histological exacerbation of glomerular injury.
Deficiency of tPA, the predominant plasminogen activator expressed in glomeruli, also exacer-
bated disease. uPA deficiency reduced glomerular macrophage infiltration and did not signifi-
cantly exacerbate disease. uPA receptor deficiency did not effect the expression of GN. These
studies demonstrate that plasminogen plays an important role in protecting the glomerulus
from acute inflammatory injury and that tPA is the major protective plasminogen activator.
 
T
 
he plasminogen/plasmin system has important func-
tions in the dissolution of fibrin and in the breakdown
of other extracellular matrix proteins (1). It has pivotal roles
in clot lysis and wound healing (2, 3), but also has the po-
tential to influence the outcome of inflammatory processes,
particularly where fibrin and extracellular matrix deposition
play an important role (4).
Glomerulonephritis (GN) results from immunologically
mediated glomerular inflammation and is the most com-
mon cause of renal failure worldwide. Glomerular fibrin
deposits are observed in severe proliferative and in crescen-
tic forms of human GN, in which the outcome for renal
function is often poor (5). These forms of GN are associ-
ated with recruitment of T cells and monocytes (6) and
cross-linking of fibrin both in the glomerular tuft and within
Bowman’s space. Fibrin in Bowman’s space is chemotactic
for macrophages (7). This accumulation of macrophages
and fibrin forms the histological appearance of a crescent
(8, 9).
The glomerulus, being a complex filter, is particularly
susceptible to injury induced by local deposition of fibrin
and other matrix proteins. Defibrination studies have dem-
onstrated that fibrin is an important mediator of glomerular
injury and crescent formation in experimental GN (8, 9).
Local dysregulation of coagulation (10) and fibrinolysis (11)
may contribute to glomerular fibrin deposition. Upregula-
tion of tissue factor has been demonstrated in experimental
(12) and human crescentic GN (13). Dysregulation of the
plasminogen/plasmin system, with decreased glomerular fi-
brinolytic activity, decreased tissue type plasminogen acti-
vator (tPA) and increased plasminogen activator inhibitor-1
(PAI-1) has also been demonstrated in experimental cres-
centic GN (11) and in human GN (14).
The extent to which local generation of plasmin plays a
protective role in preventing glomerular fibrin deposition
in crescentic GN is not known. Plasmin can cleave cross-
linked fibrin, directly degrade matrix proteins (1) and can
activate matrix metalloproteinases (15), suggesting a pro-
tective function for plasmin in the glomerulus. Conversely,
plasmin may activate latent transforming growth factor-
 
b
 
(16), which promotes matrix deposition (17), enhances
PAI-1 production (17) and down regulates plasminogen
activator production in the kidney (18).
To evaluate the plasminogen/plasmin system in immune
initiated glomerular injury, proliferative GN was induced in
mice with genetic deficiencies of key molecules of this sys-
tem. These included mice deficient in plasminogen (
 
Plg
 
2/2
 
)
(19), mice with combined deficiencies of tPA and uPA
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(
 
tPA
 
2/2
 
:uPA
 
2/2
 
) (2), mice with single deficiencies of
either tPA (
 
tPA
 
2/2
 
) or urokinase-type plasminogen acti-
vator (
 
uPA
 
2/2
 
) (2) and mice deficient in the cell surface
receptor for uPA, (
 
uPAR
 
2/2
 
) (20). Mice were compared
with their appropriate genetically unmodified (or wild-type
[WT]) mice in each case. GN was induced by planting an
exogenous Ag, sheep anti–mouse GBM globulin, in the
glomeruli of mice previously sensitized to sheep globulin
(SG) which induced a rapidly progressive, proliferative GN
with renal impairment in WT mice.
 
Materials and Methods
 
Study Design.
 
Mice deficient in plasminogen, tPA, uPA, both
tPA and uPA, and uPAR were created and characterized as previ-
ously described (2, 19, 20). Mice were 48–69 d old and clinically
free of disease at induction of GN. Studies of 
 
Plg
 
2/2
 
, 
 
tPA
 
2/2
 
,
 
uPA
 
2/2
 
, 
 
uPAR
 
2/2
 
 mice and their WT mice used male mice
weighing between 20 and 30 g, except 
 
Plg
 
2/2
 
 mice, which
weighed between 10.7 and 21.3 g. 
 
tPA
 
2/2
 
:uPA
 
2/2
 
 mice and
their WT controls were female. WT female mice weighed 16.9
to 20.5 g and 
 
tPA
 
2/2
 
:uPA
 
2/2
 
 mice weighed 13.7 to 18.8 g.
Sheep anti–mouse GBM globulin was prepared as previously
described (21). Mice were sensitized with 2 mg SG in 200 
 
m
 
l of
Freund’s Complete Adjuvant (Sigma Chemical Co., Castle Hill,
Australia) injected s.c. at two sites. 5 mg of sheep anti–mouse
GBM globulin was injected i.v. after 10 d to initiate glomerular
disease. The dose of anti-mouse GBM globulin was reduced to 4 mg
for mice weighing between 15.0 to 19.9 g and to 3 mg for mice
less than 15.0 g in weight.
Animals were studied 10 days after anti-GBM globulin injection.
 
tPA
 
2/2
 
 mice (
 
n
 
 
 
5 
 
10), 
 
uPA
 
2/2
 
 mice (
 
n
 
 
 
5 
 
9), and 
 
uPAR
 
2/2
 
mice (
 
n
 
 
 
5 
 
8) were matched with WT mice (
 
n
 
 
 
5 
 
9), with equal
fractions of each WT genotype. Female 
 
tPA
 
2/2
 
:uPA
 
2/2
 
 mice
(
 
n
 
 
 
5 
 
5) were matched with female WT mice (
 
n
 
 
 
5 
 
7). Because of
severity of disease in the 
 
Plg
 
2/2
 
 mice (
 
n
 
 
 
5 
 
8), they were studied
8 days after induction of disease, together with WT mice (
 
n
 
 
 
5 
 
4).
Two 
 
Plg
 
2/2
 
 mice, which were killed because of severe disease
(at days 6 and 7), and another 
 
Plg
 
2/2
 
 animal that died on day 7
of disease were included in the analysis.
 
Assessment of Glomerular Injury.
 
Renal tissue was fixed in Bouin’s
fixative, embedded in paraffin, cut in 3
 
 
 
m
 
m sections and stained
with periodic acid Schiff’s stain (PAS) for histological analysis.
Glomerular cellularity was determined by counting cell nuclei in
at least 20 glomeruli per animal and results expressed as cells per
glomerular cross section (cells/gcs). The presence of PAS
 
1
 
 mate-
rial within glomeruli was scored semiquantitatively in a minimum
of 50 glomeruli per mouse as follows: 0 
 
5
 
 no deposition of
PAS
 
1
 
 material, 1 
 
5
 
 up to one third of the cross-sectional area of
the glomerulus staining PAS
 
1
 
, 2 
 
5
 
 one third to two thirds in-
volvement, 3 
 
5
 
 greater than two thirds involvement. Crescent
formation (defined as the presence of 3 or more layers of cells in
Bowman’s space) was assessed (minimum of 50 glomeruli per
mouse) and results expressed as a percentage incidence.
Tissue sections (6 
 
m
 
m) were stained to demonstrate macro-
phages using a three-layer immunoperoxidase technique, as pre-
viously described (22). The primary Ab was M1/70 (monoclonal
anti-mouse Mac-1; American Type Culture Collection [ATCC],
Rockville, MD). Sections of spleen provided a positive control
for each animal and protein G–purified rat Ig was substituted for
the primary Ab to provide a negative control. A minimum of 20
glomeruli were assessed per mouse and results expressed as cells/gcs.
Fibrin immunofluorescence was performed on sections (4 
 
m
 
m)
cut from frozen tissue. An IgG fraction of goat anti–mouse fibrin/
fibrinogen serum (Nordic Immunological Laboratories, Drawer,
CA) was conjugated to digoxigenin (Boehringer Mannheim, Castle
Hill, Australia) and used at a concentration of 35 
 
m
 
g/ml. Binding
of the primary Ab was detected with FITC-conjugated sheep
anti-digoxigenin Fab fragments (Boehringer Mannheim) at a di-
lution of 1 in 50. Glomerular fibrin deposition was assessed semi-
quantitatively (minimum of 30 glomeruli per mouse) using the
scoring system described for the assessment of glomerular PAS
 
1
 
material.
Serum creatinine (sCr) was measured by the alkaline picric acid
method by autoanalyzer (Cobas Bio, Roche Diagnostics, Basel,
Switzerland). As sCr is proportional to weight, values for 
 
Plg
 
2/2
 
and 
 
tPA
 
2/2
 
:uPA
 
2/2
 
 mice were adjusted to the mean weight of
their WT group at the end of the experiment.
 
Measurement of Circulating Mouse Anti–Sheep Globulin Anti-
body.
 
Mouse anti–sheep globulin titers were assessed by ELISA
on serum collected at the end of the experiment. Microtiter plates
were coated with 10 
 
m
 
g/ml SG in carbonate/bicarbonate buffer
(pH 9.5), washed, blocked with 1% BSA, then incubated with
dilutions of mouse serum. Bound mouse Ig was detected with
horseradish peroxidase conjugated rabbit anti–mouse Ig (Sigma
Chemical Co.) at a dilution of 1 in 2,000 using 0.1 M 2,2
 
9
 
-azino-
di-3-ethylbenzthiazoline sulphonate (ABTS; Boehringer Mann-
heim, Castle Hill, Australia) in 0.02% H
 
2
 
O
 
2
 
 as the substrate. The
absorbance at 405 nm was read on a microtiter plate reader. Se-
rum from each mouse was tested in serial dilutions from 1 in 100
to 1 in 126,000, with serum from six non-immunized mice used
as negative controls.
 
Statistics.
 
Results are expressed as the mean 
 
6
 
 SEM. Signifi-
cances of differences were determined by the unpaired 
 
t
 
 test for
the 
 
Plg
 
2/2
 
 and 
 
tPA
 
2/2
 
:uPA
 
2/2
 
 mice and their respective WT.
Multiple group comparisons (i.e., 
 
tPA
 
2/2
 
, 
 
uPA
 
2/2
 
, 
 
uPAR
 
2/2
 
and WT mice) were analyzed by ANOVA, followed by Fisher’s
protected least significant differences (PLSD) test.
 
Results
 
Effects of Plasminogen and Plasminogen Activator Deficiencies
on Histological Features of GN.
 
All WT mice developed pro-
liferative GN (Fig. 1 
 
A
 
) with occasional glomeruli exhibiting
crescent formation. Areas of basement membrane thickening
were demonstrated by silver methenamine staining (not
shown) and segmental fibrin deposition was observed within
the glomerular tuft by direct immunofluorescence (Fig. 1
 
B
 
). Glomeruli of both 
 
Plg
 
2/2
 
 and 
 
tPA
 
2/2
 
:uPA
 
2/2
 
 mice
were more severely affected, with tuft necrosis and rela-
tively hypocellular glomeruli (Fig. 1, 
 
C
 
 and 
 
E
 
). Despite this
relative hypocellularity, there were more macrophages within
glomeruli and significantly increased numbers of glomeruli
exhibiting crescent formation compared to their respective
WT controls (Table 1). Crescents in the 
 
Plg
 
2/2
 
 and 
 
tPA
 
2/2
 
:
uPA2/2 animals were larger than those found in WT mice
and contained both cellular elements (Fig. 1, C and E, ar-
rowed), and fibrin (Fig. 1, D and F, arrowed). Deposition of
PAS1 material within glomeruli was significantly increased
(Table 1) indicating more extra cellular matrix deposition in
nephritic Plg2/2 and tPA2/2:uPA2/2 mice, compared
to WT animals.965 Kitching et al. Brief Definitive Report
Figure 1. Photomicrographs
of representative glomeruli from
WT mice (A and B, Plg-defi-
cient mice (C and D) and com-
bined tPA- and uPA-deficient
mice (E and F) with GN dem-
onstrating light microscopic ap-
pearances (PAS stain, magnifica-
tion 3350) and fibrin deposition
(immunofluorescence, magnifi-
cation  3400). WT mice with
GN at day 10 showed prolifera-
tive GN (A) and segmental fibrin
deposition within the glomerular
tuft (B). Plg-deficient mice at day
8 developed hypocellular glom-
eruli with extensive deposition
of PAS1 material in the glomer-
ular tuft and cellular crescent for-
mation (C, arrowed) and extensive
fibrin deposition within the glom-
erular tuft and in Bowman’s
space (D, arrowed). Mice with
combined tPA, uPA deficiency at
day 10 showed similar histologi-
cal features to Plg-deficient mice
(E) and similar extensive glomer-
ular fibrin deposition (F).
Of mice deficient in a single plasminogen activator or
uPAR, only tPA2/2 mice exhibited histologically more
severe disease with increased glomerular hypercellularity
and increased numbers of glomerular macrophages. Depo-
sition of PAS+ material was increased compared to WT
mice (Table 1) but did not reach the extent of the Plg2/2
or  tPA2/2:uPA2/2 mice. Mice deficient in uPA had
fewer macrophages infiltrating glomeruli compared to WT
mice, but no other differences in the histological appear-
ances or quantitative indices of renal injury (Table 1). Ne-
phritic uPAR2/2 mice showed similar histological appear-
ances to WT mice (Table 1).
Effect of Plasminogen and Plasminogen Activator Deficiencies
on Glomerular Fibrin Deposition in GN. In contrast to the
segmental fibrin deposition observed only within the glom-
erular tuft in WT mice (Fig. 1 B), Plg2/2 and tPA2/2:
uPA2/2 mice developed extensive glomerular fibrin depo-
sition within the glomerular tuft and in Bowman's space
(Fig. 1, D and F). Semi-quantitative scoring of the extent
of glomerular fibrin deposition confirmed that these differ-
ences were statistically significant compared to their WT
controls (Fig. 2). Mice deficient in tPA also showed signifi-
cant increases in glomerular fibrin deposition over WT
(Fig. 3), though the extent of glomerular fibrin deposition
did not reach that of the Plg2/2 or the tPA2/2:uPA2/2
mice. There were no significant changes in glomerular fi-
brin deposition in nephritic uPA2/2 and uPAR2/2 mice
compared to WT mice.
Effect of Plasminogen and Plasminogen Activator Deficiencies
on Renal Function in GN. The importance of the increased966 Glomerulonephritis in Fibrinolytic Gene Knock-Out Mice
glomerular deposition of fibrin and other matrix proteins
induced by deficiency of plasminogen activation was dem-
onstrated by the increased impairment of renal function ob-
served in plasminogen or plasminogen activator-deficient
mice. Plg2/2 and tPA2/2:uPA2/2 mice developed more
severe renal failure, measured by sCr compared to their ap-
propriate WT groups (Fig. 2). Mice deficient in tPA alone
also developed more renal impairment compared to their
WT control. uPA2/2 mice showed a trend towards more
severe renal impairment (sCr P 5 0.08 compared to WT).
The severity of renal impairment of nephritic uPAR2/2
mice was unchanged from that of WT mice with GN (Fig. 3).
Assessment of Systemic Immune Responses. In addition to
the activity of the coagulation and fibrinolytic systems, the
extent of immune response to the disease initiating antigen
is important in determining the severity of injury in this
model of GN. Although deficiencies of the plasminogen/
plasmin system are not known to modulate immune re-
sponses, the specific immune response to the nephritogenic
Ag (SG) was quantified in the various groups of mice with
GN by measurement of circulating levels of mouse anti–sheep
globulin antibodies. Ab titers, measured by ELISA at dilu-
tions of sera from 1 in 100 to 1 in 102,400, were not signif-
icantly different for any genetically deficient mice compared
with their WT control group, except in Plg2/2 mice that
showed slightly lower absorbance values at the two highest
antibody dilutions. These minor differences are unlikely to
significantly modulate the expression of GN and could not
contribute to the more severe disease seen in these Plg2/2
mice.
Discussion
These studies demonstrate that generation of plasmin
plays a critical role in protecting glomerular structure and
function in rapidly progressive GN. A similar degree of se-
vere glomerular damage was observed with plasminogen
deficiency and combined deficiency of tPA and uPA, sug-
gesting that these two plasminogen activators contribute
the major plasminogen activating activity in GN. This sup-
ports the earlier observation that tPA and uPA are the only
two physiologically significant plasminogen activators in
mice (19). Mice deficient in tPA alone also developed
more severe renal injury than WT mice, but not to the
extent observed in combined PA or the Plg-deficient mice.
More severe GN did not develop in uPA2/2 or uPAR2/2
mice.
Table 1. Histological Features of GN in Mice
Group
Glomerular
crescent formation
PAS1 Material
(0-31)
Glomerular
Hypercellularity
Glomerular
Macrophages
% glomeruli cells/gcs cells/gcs
WT (Plg) 4.8 6 1.9 0.79 6 0.08 66.3 6 1.2 1.47 6 0.17
Plg 2/2 18.1 6 3.1* 1.94 6 0.27* 54.0 6 1.9‡ 4.85 6 1.03*
WT (tPA, uPA) 2.9 6 1.2 0.64 6 0.09 58.6 6 2.8 1.38 6 0.05
tPA2/2:uPA2/2 15.4 6 2.9§ 1.55 6 0.24§ 45.3 6 4.4* 3.92 6 0.52¶
WT 3.9 6 1.9 0.75 6 0.20 60.1 6 1.2 1.46 6 0.14
tPA2/2 16.1 6 8.0 1.27 6 0.05¶ 69.7 6 1.6¶ 2.22 6 0.28‡
uPA2/2 6.1 6 1.3 0.80 6 0.07 62.4 6 2.2 0.82 6 0.08*
uPAR2/2 9.6 6 3.5 0.87 6 0.06 64.8 6 2.3 1.31 6 0.18
Comparison of histological features of GN in plasminogen (Plg2/2), combined plasminogen activator-deficient (tPA2/2:uPA2/2), tPA (tPA2/2),
uPA (uPA2/2) and uPA receptor (uPAR2/2)-deficient mice and their appropriate WT controls. Results are expressed as the mean 6 SEM.
*Results significantly different to WT at the P ,0.05 level; ‡P ,0.01 level; §P ,0.005 level; ¶P ,0.001 level (Fisher’s PLSD test).
Figure 2. Glomerular fibrin deposition and renal function (sCr) in
Plg2/2, WT (Plg), tPA2/2:uPA2/2 and WT (tPA:uPA) mice (* indi-
cates P ,0.05, ‡P ,0.01, ¶P ,0.001, compared to appropriate WT con-
trol by unpaired t test).967 Kitching et al. Brief Definitive Report
In the initial characterization of mice with combined de-
ficiencies of tPA and uPA, minor spontaneous renal fibrin
deposition was reported in a minority of animals beyond
the age of 2 to 3 mo (2). However, in this study disease was
induced in tPA2/2:uPA2/2 mice that were younger than 2
mo old to avoid any possibility that spontaneous glomerular
fibrin deposition may significantly influence the results. In
the original description of Plg2/2 mice, dilated renal
pelvises had been noted in four mice, without fibrin depo-
sition (19). None of the Plg2/2 mice in the current study
had macroscopic or microscopic evidence of pelvicalyceal
dilatation or obstruction.
There was a significantly increased propensity to form
crescents in glomeruli of mice with plasminogen or com-
bined plasminogen activator deficiency. Crescents are the
result of accumulation of fibrin and macrophages, together
with proliferation of glomerular epithelial cells in Bow-
man’s space. They are indicative of severe glomerular injury
and a poor outcome for renal function. Fibrin has previ-
ously been shown to be an important chemotactic stimulus
for accumulation of macrophages in Bowman’s space and
crescent formation (7). The enhanced crescent formation
and macrophage infiltration in Plg2/2 and tPA2/2:
uPA2/2 mice is consistent with the observation that en-
hanced glomerular fibrin accumulation occurring in the
absence of local plasmin generation provides a greater stim-
ulus for inflammatory cell recruitment and crescent forma-
tion. The more intense inflammatory reaction resulted in
necrosis of the glomerular tuft and hypocellular glomeruli.
tPA is the predominant PA within mouse (23), rabbit
(11) and human (24, 25) glomeruli and is produced mainly
by glomerular endothelial cells. The major site of uPA pro-
duction within the murine kidney is the tubular epithelium
(23), although human glomerular epithelial cells in culture
also produce uPA (24, 26) and uPA immunofunctional ac-
tivity has been demonstrated in rabbit (11) and human glo-
meruli (25). uPA has been proposed to have a role in main-
tenance of tubular patency (23).
Mice deficient in tPA alone showed significantly increased
renal failure, glomerular hypercellularity, glomerular macro-
phage numbers, glomerular fibrin deposition and deposition
of PAS1 material within glomeruli. They also demonstrated
a trend towards increased crescent formation. Glomerular
capillary thrombosis was minimal in nephritic tPA2/2 mice
and their glomeruli were hypercellular. However, the se-
verity of injury in these mice was not sufficient to cause ne-
crosis of the glomerular tuft.
Mice deficient in uPA alone did not show significant dif-
ferences in histological indices of disease from WT mice,
but did show a trend towards increased renal impairment.
The significance of this result is unclear, but the extensive
expression of uPA in renal tubular epithelial cells of normal
mice suggests that tubular dysfunction may have contrib-
uted to any increased renal impairment in uPA2/2 mice.
The demonstration of significantly reduced glomerular mac-
rophage infiltration in uPA2/2 mice supports the hypoth-
esis that uPA assists migration of macrophages to sites of in-
flammatory injury.
The increased renal impairment, fibrin deposition and
other histological indices of disease in the tPA2/2 mice
suggest a more important role for tPA in protecting glom-
eruli against inflammatory injury, but do not exclude a role
for uPA. However, the more severe glomerular injury in
mice deficient in both plasminogen activators implies that
the effects of uPA deficiency in glomerular inflammation
become evident in the absence of tPA.
Deficiency of the uPA receptor did not significantly
modify the histological or functional manifestations of GN.
The observation that glomeruli of uPAR-deficient mice
contained similar numbers of macrophages to WT mice
suggests that unlike uPA, uPAR is not important in mac-
rophage infiltration into nephritic glomeruli. In normal mice,
uPAR mRNA is expressed only at low levels in the kid-
ney, in contrast to the abundant renal expression of uPA
mRNA (27). Sites of uPA expression in the kidney do not
correspond well to its receptor (27), suggesting that in the
kidney uPA can act independently of uPAR. Although a
prominent role for uPA and uPAR could not be demon-
strated in this short term model of renal injury, this does
not preclude a significant role for these proteins in chronic
renal injury, where prolonged accumulation of matrix pro-
teins leads to renal scarring and glomerulosclerosis.
In summary, these studies demonstrate an important pro-
tective role for plasminogen and plasminogen activators in
acute inflammatory renal injury associated with crescentic
GN. They are consistent with previous observations that
tPA and uPA appear to be the major plasminogen activa-
tors in vivo but also suggest that the major protective role
in acute inflammatory glomerular injury is attributable to
tPA. uPA facilitates recruitment of macrophages into ne-
phritic glomeruli. The uPA receptor does not appear to play
any significant role in protecting the glomerulus in GN.
Therapies aimed at enhancing or replacing fibrinolytic ac-
tivity in crescentic GN may be of benefit in human disease.
Figure 3. Glomerular fibrin deposition and renal function (sCr) in
tPA2/2, uPA2/2, uPAR2/2, and WT mice. §P ,0.005 compared to
WT control by Fisher’s PLSD test.968 Glomerulonephritis in Fibrinolytic Gene Knock-Out Mice
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